Squibb (BMS) to develop and commercialize novel therapies targeted
against the Liver X Receptor. As a result of the extension, we expect
to receive additional research funding in the amount of $7.5 million.
BMS also has the option to extend the collaboration by an additional
* Our wholly-owned subsidiaries Exelixis Plant Sciences, Inc. and
Agrinomics, LLC entered into a transaction with Agrigenetics, Inc., a
wholly-owned subsidiary of The Dow Chemical Company, which included
the sale of tangible and intangible assets and a research funding
agreement focused on the development of new tools for gene discovery
and validation of novel crop traits.
* We closed a public equity offering of seven million shares of common
stock, with net proceeds of approximately $71.9 million, after
deducting offering expenses.
We presented phase 2 data for XL647 and XL880, and phase 1 data for XL184, XL765 and XL147 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. In total, 13 abstracts were accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.
We also announced that a recently completed phase 2 trial of XL784 did
not meet its primary endpoint of reducing proteinuria compared with placebo
in patients with proteinuria associated with diabetic nephropathy. Various
subgroup analyses suggest that the compound may have potential to benefit
patients with this disease. We submitted the XL784 data report to GSK on
October 22, 2007 and GSK has 90 days from the date of submission of the
data report to determine whether it will select XL784 for further clinical
|SOURCE Exelixis, Inc.|
Copyright©2007 PR Newswire.
All rights reserved